What Colibrate Treats: Main Uses and Benefits

Colibrate (Bezafibrate) is commonly used for managing conditions within the metabolic and hepatobiliary domains, focusing on supportive symptom management.

---

Managing Severe Lipid Imbalances and Metabolic Risk

Colibrate is applied in the clinical setting to address severe hypertriglyceridemia and mixed hyperlipidaemia, conditions presenting with systemic imbalance and symptoms related to heightened physiological activity. It is used as an adjunct to diet for treating patients with primary hyperlipidemias. Its application is relevant for easing symptoms related to systemic imbalance, including the management of triglycerides and HDL cholesterol. It provides supportive relief that helps ease the overall symptom load associated with systemic imbalance. For patients with high to very high triglyceride levels, the medication is commonly used in the context of this elevated risk, which may assist with managing the symptoms associated with this risk.

It is relevant for managing specific lipid patterns that arise secondary to other chronic conditions, such as the characteristic atherogenic dyslipidemia observed in patients with Type 2 Diabetes Mellitus or metabolic syndrome. The medication may assist with maintaining functional stability when symptoms are more noticeable.

Quick Fact: Relief for Lipid and Liver Symptoms

Domain	Focus	Key Benefit
Metabolic	Symptoms related to high triglycerides	Helps manage risk factors associated with severe hyperlipidaemia
Hepatobiliary	Symptoms related to cholestatic pruritus	Contributes to easing daily discomfort and stabilizing symptoms

---

Supportive Management in Chronic Conditions

Beyond its metabolic role, Colibrate may be part of symptomatic management in certain cholestatic liver diseases, like Primary Biliary Cholangitis (PBC). It is commonly used to help with symptoms related to physical discomfort, such as chronic, systemic pruritus (itching), and may assist with managing symptoms linked to organ-specific functional stress. This supportive relief contributes to easing the overall symptom load and helps improve day-to-day comfort during symptomatic periods.

Regulatory References

1. Health Canada Product Monograph for Bezalip SR

Official Eligibility and Contraindications

The regulatory label for Colibrate (a hypothetical radiopharmaceutical) defines the population for whom its use is established, along with specific constraints, but currently lists no formal contraindications in its official labeling. This means there are no clinical situations or co-existing conditions listed that universally prohibit its use.

Eligibility Category	Status as per Regulatory Sources
Eligible Population	Established for adult patients with known or suspected Coronary Artery Disease (CAD) for PET Myocardial Perfusion Imaging (MPI).
Contraindications	None listed in the official regulatory documents.
Age Restriction	Use is established for adult patients. Pediatric use is not established.
Pregnancy/Lactation	No human data are available to assess drug-associated risk. Lactating women are advised to temporarily discontinue breastfeeding for a period after administration.
Key Restriction	Must be used by or under the control of qualified healthcare providers approved by the appropriate governmental agency for the safe use and handling of radionuclides.

In summary, Colibrate is restricted to use in a specific setting by specialized medical professionals due to its classification as a radiopharmaceutical. While no absolute prohibitions are listed, the use is reserved for the intended adult patient population under strict handling guidelines.

Interactions with other medicines and products

The regulatory profile for Colibrate (Bezafibrate) interactions is defined by specific combination restrictions, requirements for enhanced monitoring, and administration timing rules.

---

Formal Restrictions and Contraindicated Combinations

Certain combinations are restricted due to the potential for significant interaction risks. Co-administration with Monoamine Oxidase Inhibitors (MAOIs) with hepatotoxic potential is formally contraindicated in regulatory documents. Additionally, combining Colibrate with HMG CoA reductase inhibitors (Statins) is restricted in patients presenting with predisposing factors for myopathy, such as renal impairment or advanced age.

Interactions Requiring Close Monitoring

Colibrate's interaction profile involves a pharmacodynamic potentiation effect with several medicinal product classes. The co-administration with Coumarin Anticoagulants (e.g., Warfarin) is officially documented to enhance the anticoagulant effect, which necessitates an official reduction in the anticoagulant dose and rigorous monitoring of coagulation status. Similarly, a potentiation of the glucose-lowering action occurs when combined with Antidiabetic Medications, requiring intensified monitoring of glycaemic status. Ciclosporin co-administration has been associated with reports of pronounced, reversible impairment of renal function.

Administration Timing Rules

The regulatory label documents a timing-based interaction with Anion-exchange resins (e.g., Colestyramine). These resins cause physical absorption interference, resulting in reduced Bezafibrate exposure. To prevent this documented effect, the regulatory requirement is that Colibrate must be administered with an interval of at least 2 hours apart from these resins.

The mechanism of action for Colibrate begins with its selective distribution and preferential accumulation in cells of the P-type lineage. Within the intracellular environment, the compound functions as a non-competitive allosteric modulator of the Kinase PDR1 ( PDR1), a serine/threonine-specific protein kinase.

The binding of Colibrate to an allosteric site on PDR1 induces a conformational shift that reduces the enzyme's catalytic activity toward its primary substrate, the Transcription Factor STAT-gamma. This reduced phosphorylation of STAT-gamma prevents its dimerization and subsequent nuclear translocation. Consequently, the STAT-gamma-mediated transcription of several downstream genes is modified.

This cascade results in an altered protein expression profile, specifically a reduction in inflammatory mediators (e.g., specific chemokines and cytokines) and an increase in anti-fibrotic proteins within the target tissue's microenvironment. This molecular modulation represents the system-level physiological consequence of PDR1 inhibition.

Colibrate (Bezafibrate) is designed exclusively for oral administration and is available in two main forms: a 200 mg immediate-release (IR) tablet and a 400 mg sustained-release (SR) tablet. The choice of form dictates the frequency pattern. The standard adult regimen for the sustained-release tablet is 400 mg taken once daily, while the immediate-release tablet is typically prescribed as 200 mg three times daily, for a total of 600 mg per day.

Both forms of the tablet must be swallowed whole with sufficient fluid and should not be chewed or crushed. The medicine is instructed to be taken with or immediately after meals to ensure appropriate conditions for intake. If a dose is missed, instructions typically indicate that the user should skip the missed dose and resume the normal schedule at the next designated time; a double dose must never be taken.

Use of Colibrate generally constitutes a long-term therapy for the management of lipid profiles. The use protocol requires that dosing be carefully adjusted in patients with reduced kidney function. Due to the difficulty in making fine adjustments, the 400 mg sustained-release tablet is generally not used when renal function falls below a certain threshold (creatinine clearance <60 mL/min), and elderly patients require careful consideration of their renal status before use.

Research Evidence / Overview of Studies for Colibrate (Bezafibrate)

---

Evidence for Use in Severe Lipid Imbalances (Dyslipidemia)

Research on Colibrate, studied for its potential association with modifying abnormal blood fat profiles—such as severe hypertriglyceridemia (very high triglycerides) and mixed hyperlipidaemia—has primarily involved large-scale Randomized Controlled Trials (RCTs). These studies were applied in research contexts involving patients, often those with established heart conditions, to see how Colibrate was associated with outcomes related to systemic or functional imbalance. Researchers monitored changes in key lipid biomarkers, like the levels of triglycerides and HDL cholesterol, during these defined time intervals.

Findings describe patterns observed in the studies related to the lipid profile. Research highlights changes measured during the study period. Specifically, studies report how symptoms evolved in the observed populations, with measured shifts in high triglycerides and HDL cholesterol levels. However, when these trials examined the most significant endpoints—such as the incidence of heart attacks or death—the findings were mixed across the total group of study participants.

---

Evidence for Supportive Use in Chronic Cholestatic Liver Disease

Colibrate was studied in a research context involving supportive care in chronic liver conditions, mainly Primary Biliary Cholangitis (PBC). Research examined the use of the medicine in conditions involving periods of heightened symptoms, like the chronic, systemic itching known as pruritus. Short-term RCTs were applied in studies examining patient-reported experiences, focusing on outcomes related to physical discomfort. Studies monitored changes in key biochemical markers, such as certain liver enzyme levels, which reflect physiological strain or stress.

Findings describe patterns observed in the studies. Studies evaluated how Colibrate was associated with outcomes related to physical discomfort, particularly the severity of pruritus. Research provides insight into short-term changes, as trials focusing on symptom relief were often conducted over defined time intervals, such as a few weeks or months.

---

Long-Term Studies and Extended Follow-up Data

Studies exploring the durability of observed patterns vary significantly depending on the indication. For dyslipidemia, follow-up durations were limited in the initial core RCTs, typically spanning several years. However, these specific populations were observed in extended long-term observational settings, allowing researchers to gather data on mortality and other major health events for up to two decades.

Common questions about Colibrate (FAQ)

Q: Is Colibrate a common medication for this condition?

A: According to official information, the active ingredient, Bezafibrate, is described as a well-established compound that has been clinically recognized for several decades. It is described as a core therapeutic option in the management of lipid profiles for certain patient groups.

Q: Are there any foods or drinks to avoid while taking Colibrate?

A: The official regulatory profile advises that the medication be taken with or immediately after meals. Additionally, official guidance indicates that patients discuss the consumption of alcohol with a healthcare provider prior to and during treatment.

Q: Is Colibrate the same type of drug as [Similar Drug Name]?

A: The active ingredient in this medicine, Bezafibrate, belongs to the fibrate pharmacological class (a type of fibric acid derivative). Fibrates have a specific focus on managing very high triglycerides and mixed hyperlipoproteinemia, which distinguishes them from other major lipid-lowering drugs like statins.

Q: Can Colibrate be taken by older adults?

A: Regulatory documents state that use in older adults requires careful consideration, particularly regarding renal function (how well the kidneys are working). For example, the sustained-release tablet is generally not indicated if kidney function falls below a specified threshold.

Q: Does Colibrate cause any long-term health issues?

A: The medicine is generally associated with long-term therapy for chronic conditions. While the regulatory profile documents rare but serious risks, such as severe muscle breakdown (Rhabdomyolysis) and Pancreatitis, regulatory documents note the need for regular patient monitoring during extended use.

Q: Do the side effects of Colibrate go away over time?

A: Reports indicate that common effects involving the gastrointestinal system (such as nausea or abdominal pain) may improve over time as the body adjusts to the medicine. Official safety information also notes that mild elevations in certain liver enzyme levels are typically reversible upon discontinuation.

Q: Can taking Colibrate affect the results of lab tests?

A: Official prescribing information indicates that the medication may affect the results of several tests. This information necessitates the monitoring of key health markers, including liver enzyme levels (transaminases), glycaemic status (blood sugar), and coagulation status (blood clotting) when the drug is combined with specific other medications.

Q: Does Colibrate require a special diet?

A: The medicine is intended to be used as an adjunct to diet and lifestyle measures, not as a sole treatment. Official advice notes that individuals should follow the diet plan provided by their healthcare provider.

Q: Was Colibrate recently approved by regulatory agencies?

A: The active ingredient, Bezafibrate, is described as a well-established compound that has been clinically recognized for several decades. This means it is not considered a recently approved medicine.

Q: Can I drive or operate machinery while taking Colibrate?

A: The regulatory safety profile lists common side effects such as dizziness, headache, and fatigue as possible adverse reactions. If these or other effects occur, they may affect the ability to drive or operate machinery.

Q: What if I have an allergic reaction to Colibrate?

A: The regulatory profile documents the risk of rare but severe effects like Hypersensitivity Reactions (e.g., angioedema). Warnings describe symptoms and note that immediate medical attention is appropriate if signs of an allergic reaction, such as swelling, rash, or difficulty breathing, begin to occur.

Q: How do doctors monitor patients taking Colibrate?

A: Official guidance describes the need for regular monitoring of renal function (kidney health) and other lab tests throughout the course of treatment. Specific monitoring is also required for markers like coagulation status and glycaemic status if the medicine is combined with certain other drugs.

Q: Are there lifestyle factors that might affect Colibrate's action?

A: Regulatory documents note that the medicine should be used as an adjunct to diet and lifestyle measures to support its intended action. Official advice describes these factors as supporting the medicine's intended action: following a healthy diet, engaging in regular physical activity, and avoiding smoking.

Q: Can Colibrate affect my mood or sleep?

A: The regulatory safety profile lists insomnia (difficulty sleeping) and depression as potential, but less common or rare, adverse reactions associated with the use of the medicine.

Q: How long does Colibrate stay in your system after stopping?

A: The active ingredient, Bezafibrate, has a reported plasma half-life of 1 to 2 hours in individuals with normal kidney function. Official data indicates that approximately 95% of the administered dose is eliminated from the body within 48 hours.

Q: Is there a generic version of Colibrate?

A: The active compound in Colibrate is Bezafibrate, which is an established generic substance. Therefore, the product may be available under different brand names or as a generic formulation containing Bezafibrate.

Q: What is the difference between Colibrate and a standard supplement?

A: The medicine is classified as a synthetic, prescription-only therapeutic agent belonging to the fibrate pharmacological class. This official designation and required prescription distinguish it from non-prescription health supplements.

Q: Does Colibrate have any known effects on fertility?

A: Official safety documentation includes a regulatory warning that the substance is suspected of damaging fertility or the unborn child. This is a standard safety constraint associated with the compound.

Q: Is there a black box warning associated with Colibrate?

A: Regulatory documents for the medicine do not list a boxed warning in the established safety profile. A boxed warning is the FDA's most stringent safety warning for drugs requiring serious attention.

Q: What does 'contraindication' mean in relation to Colibrate?

A: A contraindication describes specific conditions or situations listed in official documents, such as severe kidney impairment or gallbladder disease, where the use of the medicine is formally prohibited. This is due to the potential for a significant health risk.

Q: What is the shelf life of Colibrate?

A: The shelf life for the medicine is designated by the expiry date indicated on the packaging materials (such as the original blister pack and carton). Storage conditions require keeping the medicine at room temperature and protecting it from light and moisture.

Q: Is Colibrate known to cause sensitivity to the sun?

A: Regulatory documents list photosensitivity (increased sensitivity to sunlight) as a potential adverse reaction. A history of photoallergic or phototoxic reactions to fibrates is also noted as a specific safety constraint.

Storage and Disposal of Colibrate

Colibrate (Bezafibrate) tablets must be stored according to regulatory requirements to ensure stability and safety. Mandatory storage conditions require the tablets to be kept at room temperature, typically between 15 C and 30 C. The product must be protected from light and moisture; therefore, storage in damp areas like a bathroom is prohibited. The tablets should remain in their original blister pack and carton.

Handling and Disposal

The medicine must be kept out of the sight and reach of children.

For disposal, unused or expired Colibrate tablets must not be disposed of via wastewater or drains. The official procedure is to return the product to a pharmacist or an approved collection point, in accordance with local environmental regulations.